WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in ...

Duchenne muscular dystrophy patient died after being treated with the gene therapy delandistrogene moxeparvovec (Elevidys), ...

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...

Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety ...

Sarepta Therapeutics (NASDAQ:SRPT) reported a second fatality from acute liver failure in a patient treated with its gene ...

In the U.S., ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD ... You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

May 21, 2025--(BUSINESS WIRE)--Sarepta Therapeutics ... rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy. We have received feedback from the Medicines ...

"Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Sarepta Therapeutics ... moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy. We have received feedback from the Medicines & Healthcare products ...

Sarepta Therapeutics has followed through on its promise to file for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy (DMD), as it aims for a launch in the ...